Citadel Advisors
MGNX icon

Citadel Advisors’s MacroGenics MGNX Stock Holding History

Citadel Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Buy
+10,600
New +$40.1K ﹤0.01% 13123
2025
Q4 		– Sell
-27,300
Closed -$45.9K – 13528
2025
Q3 		$45.9K Buy
27,300
+12,500
+84% +$20.2K ﹤0.01% 12246
2025
Q2 		$17.9K Sell
14,800
-87,500
-86% -$127K ﹤0.01% 12125
2025
Q1 		$130K Buy
102,300
+75,200
+277% +$196K ﹤0.01% 11087
2024
Q4 		$88.1K Sell
27,100
-31,100
-53% -$112K ﹤0.01% 11657
2024
Q3 		$191K Buy
58,200
+21,300
+58% +$83K ﹤0.01% 10216
2024
Q2 		$157K Buy
36,900
+8,400
+29% +$81.8K ﹤0.01% 10277
2024
Q1 		$420K Buy
28,500
+23,400
+459% +$354K ﹤0.01% 8764
2023
Q4 		$49.1K Buy
5,100
+1,200
+31% +$8.3K ﹤0.01% 11798
2023
Q3 		$18.2K Sell
3,900
-3,800
-49% -$18.9K ﹤0.01% 12694
2023
Q2 		$41.2K Buy
7,700
+2,900
+60% +$17.9K ﹤0.01% 12033
2023
Q1 		$34.4K Sell
4,800
-3,000
-38% -$18.1K ﹤0.01% 12599
2022
Q4 		$52.3K Buy
+7,800
New +$42.8K ﹤0.01% 12072
2022
Q1 		– Sell
-10,300
Closed -$165K – 14193
2021
Q4 		$165K Sell
10,300
-24,500
-70% -$461K ﹤0.01% 12142
2021
Q3 		$729K Buy
34,800
+600
+2% +$14.5K ﹤0.01% 8955
2021
Q2 		$919K Sell
34,200
-12,000
-26% -$351K ﹤0.01% 8585
2021
Q1 		$1.47M Buy
46,200
+17,100
+59% +$415K ﹤0.01% 7158
2020
Q4 		$665K Buy
29,100
+19,300
+197% +$444K ﹤0.01% 7598
2020
Q3 		$247K Sell
9,800
-36,900
-79% -$1.01M ﹤0.01% 8459
2020
Q2 		$1.3M Buy
46,700
+15,400
+49% +$268K ﹤0.01% 5340
2020
Q1 		$182K Sell
31,300
-36,500
-54% -$331K ﹤0.01% 8103
2019
Q4 		$738K Buy
67,800
+23,300
+52% +$231K ﹤0.01% 6147
2019
Q3 		$568K Buy
44,500
+5,500
+14% +$79.2K ﹤0.01% 6536
2019
Q2 		$662K Buy
39,000
+26,500
+212% +$455K ﹤0.01% 6368
2019
Q1 		$225K Buy
+12,500
New +$216K ﹤0.01% 8051

Other funds holding MGNX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Citadel Advisors's MGNX Position: Q2 2026 in Review

Citadel Advisors reduced its MacroGenics (MGNX) stake by 77% in Q2 2026, selling an estimated $2.28M and leaving 179,833 shares worth $831K. The position accounts for ﹤0.01% of the portfolio, ranked #8666.

Citadel Advisors first reported a position in MGNX in Q1 2014 and has held it in 45 quarters since. The position peaked at $73.9M in Q1 2021. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • Citadel Advisors held 179,833 shares of MacroGenics worth $831K as of Q2 2026.
  • Citadel Advisors sold 602,785 MacroGenics shares in Q2 2026, an estimated $2.28M.
  • MacroGenics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8666 holding.
  • Citadel Advisors first reported a position in MacroGenics in Q1 2014 and has held it in 45 quarters since.
  • Citadel Advisors's MacroGenics position peaked at $73.9M in Q1 2021.
  • 122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.